Advertisement

Huisarts en Wetenschap

, Volume 48, Issue 7, pp 515–520 | Cite as

Nieuwe topicale immunomodulatoren voor de behandeling van atopisch eczeem

  • Esther van Zuuren
Beschouwing
  • 23 Downloads

semenvatting

1. Er is een nieuwe behandeling voor atopisch eczeem, namelijk tacrolimus en pimecrolimus.

2. Tacrolimus 0,1% is net zo effectief als een klasse-II-corticosteroïd, tacrolimus 0,03% is effectiever dan een klasse-I-corticosteroïd en pimecrolimus is minder effectief dan een klasse-II-corticosteroïd.

beschouwing corticosteroïden eczeem huidaandoeningen kinderen 

Literatuur

  1. Sillevis Smitt JH. Constitutioneel eczeem; de mogelijkheden van lokale therapie. Ned Tijdschr Geneeskd 2002;146:400-3.PubMedGoogle Scholar
  2. Van Zuuren EJ. Tacrolimus (Protopic®) geregistreerd. Gebu 2002;36:84.Google Scholar
  3. Van Zuuren EJ. Pimecrolimus (Elidel®) geregistreerd. Gebu 2003;37:92.Google Scholar
  4. IB-tekst Elidel® via www.cbg-meb.nl, geneesmiddeleninformatiebank.
  5. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-41.CrossRefPubMedGoogle Scholar
  6. Reitamo S. Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 2001;107:445-8.CrossRefPubMedGoogle Scholar
  7. Bornhövd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001;45:736-43.CrossRefPubMedGoogle Scholar
  8. Marsland AM, Griffiths CEM. The macrolide immunosuppressants in dermatology: mechanisms of actions. Eur J Dermatol 2002;12:618-21.PubMedGoogle Scholar
  9. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44:S17-27.CrossRefPubMedGoogle Scholar
  10. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RGB, Cherill R, Marshall, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis. J Am Acad Dermatol 2002;46:495-504.CrossRefPubMedGoogle Scholar
  11. Eichenfield LF, Beck LB. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-68.PubMedGoogle Scholar
  12. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. J Am Acad Dermatol 2001;44:S28-38.CrossRefPubMedGoogle Scholar
  13. Paller A, Eichenfeld LF, Leung DYM, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47-57.CrossRefPubMedGoogle Scholar
  14. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortison butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.CrossRefPubMedGoogle Scholar
  15. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46.CrossRefPubMedGoogle Scholar
  16. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Van der Valk P, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than hydrocortison acetate in children with moderate to severe atopic dermatitis:results of a randomized double-blind controlled trial. Br J Dermatol 2004;150:554-62.CrossRefPubMedGoogle Scholar
  17. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44:S65-72.CrossRefPubMedGoogle Scholar
  18. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;65:817-40.CrossRefGoogle Scholar
  19. Wahn U, Bos JD, Goodfield M, Caputo R, Kapp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1-8.CrossRefGoogle Scholar
  20. Kapp A, Kapp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.CrossRefPubMedGoogle Scholar
  21. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Braütigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-7.CrossRefPubMedGoogle Scholar
  22. Whalley D, Huels J, McKenna SP, Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parent’s quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002;110:1133-6.CrossRefPubMedGoogle Scholar
  23. Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J Am Acad Dermatol 2001;44:S39-46.CrossRefPubMedGoogle Scholar
  24. Fleischer AB, Ling M, Eichenfield L, Satoi Y, Jaracz E, Rico MJ, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47:562-70.CrossRefPubMedGoogle Scholar
  25. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-64.CrossRefPubMedGoogle Scholar
  26. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006.CrossRefPubMedGoogle Scholar
  27. Paller A, Caro I, Weinstein G, Rico MJ and the Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment in atopic dermatitis patients: open-label study. Ann Dermatol Venereol 2002;129:1S247.Google Scholar
  28. Williams H. New treatments for atopic dermatitis. BMJ 2002;324:1533-4.CrossRefPubMedGoogle Scholar
  29. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516.CrossRefPubMedGoogle Scholar
  30. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004;59:86-92.CrossRefPubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2005

Authors and Affiliations

  1. 1.

Personalised recommendations